Division of Clinical Pharmacology and Clinical Research Department, Amiens University Medical Center, 80054 Amiens, France.
EA 7517, MP3CV laboratory, CURS, Jules Verne University of Picardie, 80054 Amiens, France.
Toxins (Basel). 2018 Jun 5;10(6):229. doi: 10.3390/toxins10060229.
Non-transplanted and transplanted patients with chronic kidney disease (CKD) differ in terms of mortality and the risk of clinical events. This difference is probably due to the difference of both traditional and non-traditional risk factors. Uremic retention solutes may constitute important non-traditional risk factors in this population. In the present review, we selected a set of uremic toxins that have been associated with harmful effects, and are an appealing target for adjuvant therapy in CKD. For each toxin reviewed here, relevant studies were selected and the relationship with hard clinical outcomes of uremic toxins were compared between non-transplanted CKD patients and transplanted patients taking into account the level of glomerular filtration rate in these two situations.
非移植和移植的慢性肾脏病(CKD)患者在死亡率和临床事件风险方面存在差异。这种差异可能是由于传统和非传统危险因素的差异造成的。尿毒症潴留溶质可能是该人群中重要的非传统危险因素。在本综述中,我们选择了一组与有害作用相关的尿毒症毒素,并将其作为 CKD 辅助治疗的有吸引力的靶点。对于这里回顾的每一种毒素,我们选择了相关的研究,并比较了非移植 CKD 患者和移植患者之间与尿毒症毒素硬终点相关的关系,同时考虑了这两种情况下的肾小球滤过率水平。